Non–Small Cell Lung Cancer Coverage from Every Angle
Editor:
Gregory J. Riely, MD, PhD
Advertisement
Advertisement

Available Clinical Trials

A Phase I Study of NVL-655 in People With Advanced NSCLC or Other Solid Tumors
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab vs Standard of Care in Stage IV or Recurrent NSCLC
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs Placebo for Patients With Tumors Harboring the ALK Fusion Protein
A Phase III Study Assessing the Addition of Atezolizumab Immunotherapy to the Usual Radiation Treatment for Patients With Early NSCLC
A Randomized Phase II Trial of Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1 and 4 cm:
A Randomized, Open-label, Phase II Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects With Advanced or Metastatic PD-L1 High NSCLC Without Actionable Genomic Alterations
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I NSCLC With Primary Tumors Between 1–4 cm
An Open-Label, Randomized, Multicenter, Phase III Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Crizotinib in Treating Patients With Stage IB-IIIA NSCLC That Has Been Removed by Surgery and ALK Fusion Mutations
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
LATIFY: Ceralasertib Plus Durvalumab vs Docetaxel in NSCLC Whose Disease Progressed on or After Prior Anti–PD(L)1 Therapy and Platinum-Based Chemotherapy
Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Nonsquamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent NSCLC Following Immunotherapy
Study of Avutometinib (VS-6766) Plus Adagrasib in <em>KRAS</em> G12C NSCLC Patients
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early NSCLC
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC
Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.